The Outcomes Of Hybrid Minimally Invasive Surgical And Transcatheter Ablation For Long-standing Persistent Atrial Fibrillation
Ju Mei, Zhaolei Jiang, Nan Ma, Min Tang, Hao Liu.
Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Background: To explore the application and effectiveness of one-staged or two-staged hybrid minimally invasive surgical and transcatheter ablation for long-standing persistent atrial fibrillation (LSPAF). Methods: From Jun 2015 to Dec 2017, a cohort of 56 patients (18 female, mean age of 59.1±6.9 years) with long-standing persistent atrial fibrillation underwent one-staged (n=30) or two-staged (n=26) hybrid minimally invasive surgical and transcatheter ablation. Mean AF duration was 5.9±3.0 years. Mean left atrial diameter was 45.4±4.2mm. Mean CHA2DS2-VASc score was 2.3±1.2. Fourteen cases had a history of prior catheter ablation. All patients underwent continuous 24-hour or 48-hour holter monitoring at 3 months, 6 months, 1 year and yearly thereafter. Results: All patients successfully underwent one-staged or two-staged hybrid minimally invasive surgical and transcatheter ablation. During ablation, LSPAF was terminated in 80% (24/30) with one-staged hybrid ablation and 84.6% (22/26) with two-staged hybrid ablation. At a mean follow-up of 20.3±8.2 months, 89.3% (50/56) patients maintained sinus rhythm. Among them, 86.7% (26/30) patients with one-staged hybrid ablation maintained sinus rhythm, and 92.3% (50/56) patients with two-staged hybrid ablation maintained sinus rhythm. Six patients with recurrent AF continued to receive warfarin and amiodarone drug therapy. No death or cerebrovascular events occurred. No patient required permanent pacemaker implantation. Conclusion: One-staged or two-staged hybrid minimally invasive surgical and transcatheter ablation could be safely and effectively applied to the treatment of LSPAF. The early and midterm outcomes were satisfactory.
Back to 2019 Abstracts
